A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT

PHASE2CompletedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2010

Conditions
Peripheral T-Cell Lymphoma
Interventions
DRUG

CHOEP + G-CSF followed by BEAM

"CHOEP:~Cyclophosphamide: 750 mg/m2 i.v. day1 Hydroxydaunorubicin: 50 mg/m2 i.v. day1 Vincristine: 1.4 mg/m2 (max 2 mg) i.v. day 1 Etoposide: 100 mg/m2 i.v. day 1-3 Prednisone: 100 mg daily p.o. day 1-5~BEAM:~Carmustine: 300 mg/m2 i.v. day 1 Etoposide: 100 mg/m2 i.v. x2 daily day 2-5 Cytosine arabinoside: 200 mg/m2 i.v. x2 daily or 400 mg/m2 as continuous 24 hrs i.v. infusion, day 2-5 Melphalan: 140 mg/m2 i.v. day 6"

Trial Locations (9)

7006

St.Olavs Hospital, Trondheim

8000

Aarhus University Hospital, Aarhus

70211

Kuopio University Hospital, Kuopio

Unknown

Copenhagen Hospital, Copenhagen

Vejle Hospital, Vejle

OULO University Hospital, Oulu

Rogaland Hospital, Rogaland

0310

Oslo University Hospital, Oslo

0407

Ullevaal University Hospital, Oslo

All Listed Sponsors
collaborator

Nordic Lymphoma Group

NETWORK

lead

University of Aarhus

OTHER

NCT00791947 - A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT | Biotech Hunter | Biotech Hunter